ICON’s shares rose 12.8% following earnings, driven by notably strong gross bookings, net business wins, and sustained momentum across key segments that outweighed modest revenue softness and margin pressure.
- Gross bookings hit $3.3 billion in Q1, up 22% year-over-year and consistent with the prior quarter’s strong performance.
- Net business wins surged 42% year-over-year to $2.88 billion, resulting in a robust net book-to-bill ratio of 1.42x, signaling continued commercial strength.
- Revenue came in at $2 billion, up 1% reported but down 1.9% on a constant currency basis, reflecting earlier-period demand challenges and cancellations.
- Adjusted EBITDA margin was 15.6%, up slightly by 10 basis points sequentially despite revenue headwinds and mix shifts toward lower-margin functional services.
- Strong demand momentum persisted across pharma full service, development solutions, and biotech segments, supported by improved RFP flow and win rates.
Community Discussion